New treatment combo study for newly diagnosed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This phase 3 trial tests two different drug combinations to treat newly diagnosed multiple myeloma. It may help by aiming to control the cancer without using high-dose chemotherapy and stem cell transplant for people who can’t receive that approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma
- Your myeloma is newly diagnosed, and you are not a good candidate for high-dose chemotherapy with stem cell transplant (often due to age or other health problems)
- Your day-to-day functioning is good (ECOG score 0 to 2)
- You will not become pregnant or breastfeed during the study and for 6 months after the last dose (and you agree not to father a child during the study and for 100 days after the last dose)
- You have not had prior multiple myeloma treatment (other than limited steroid use as allowed by the study)
- You have not had certain recent serious events (like a stroke/TIA/seizure within 6 months) or certain procedures (plasmapheresis within 28 days)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
This Phase 2 trial tests two antibody medicines (teclistamab or talquetamab) given as outpatient injections, to treat multiple myeloma. It also tests preventing and treating side effects with supportive medicines, aiming to improve disease control in people who have already tried other myeloma treatments.
This trial tests a new treatment for people with newly diagnosed multiple myeloma that has not been treated before. It looks at whether adding a targeted therapy to standard treatment helps control the disease better.
This Phase 2 study tests a study treatment in adults with multiple myeloma that needs treatment. It may help by trying to improve disease control after you’ve had (or are scheduled to have) standard therapy like chemotherapy and stem cell transplant for some people.
This Phase 2 trial studies how well teclistamab works when used in combination for people age 65 and older with multiple myeloma. It aims to see whether this treatment can control the cancer safely in older patients who may not do high-dose chemotherapy or stem cell transplant.
This trial tests two combinations of drugs (Dara-RVd and Teclistamab-RVd) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if adding a newer drug called Teclistamab improves outcomes.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.